Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
AssigneeAdherex Technologies, Inc.
InventorsThomas Spector, William Peters, Donald Kufe, Brian Huber
Life of this patent
Estimating the term…
Abstract
Methods for improved administration and dosing of DPD inhibitors in combination with 5-FU and/or 5-FU prodrugs are provided, comprising first administering to a patient in need thereof a DPD inhibitor that substantially eliminates activity of the enzyme and thereafter administering 5-FU or a 5-FU prodrug, wherein the level of 5-FU or 5-FU prodrug is in substantial excess of DPD inhibitor in the patient.
Claims60
A method for treating cancer in a patient comprising first administering a DPD inhibitor and thereafter administering 5-FU or a 5-FU prodrug, wherein the 5-FU or 5-FU prodrug is administered at a dose such that at its time of administration the 5-FU or 5-FU prodrug is present in the patient in excess of the DPD inhibitor.
A method for treating cancer in a patient comprising first administering eniluracil and thereafter administering 5-FU, wherein the 5-FU is administered at a dose such that at its time of administration the 5-FU is present in the patient in excess of the DPD inhibitor.
A method for treating cancer in a patient comprising first administering eniluracil and thereafter administering 5-FU, wherein the eniluracil is administered at a dose between about 2.5-15 mg/m2, and wherein the 5-FU is administered after at least 1-4 elimination half-lives for eniluracil have passed since the eniluracil was administered.
A method for treating cancer in a patient comprising first administering eniluracil and thereafter administering 5-FU, wherein the eniluracil is administered at a dose between about 2.5-15 mg/m2, the 5-FU is administered at least about 4 hours after the eniluracil is administered, and the 5-FU is administered at a dose between about 0.5-40 mg/m2.
A method for treating cancer in a patient comprising first administering eniluracil and thereafter administering capecitabine, wherein the eniluracil is administered at a dose between about 2.5-15 mg/m2 , and wherein the 5-FU is administered after at least 1-4 elimination half-lives for eniluracil have passed since the eniluracil was administered.
An oral pharmaceutical time-release formulation comprising a DPD inhibitor and 5-FU or a 5-FU prodrug, wherein following administration of the formulation to a patient the 5-FU or 5-FU prodrug is not substantially released until at least about 4 hours after the DPD inhibitor has been released.
An oral pharmaceutical time-release formulation comprising a DPD inhibitor and a delivery vehicle, wherein the delivery vehicle facilitates the selective targeting of the DPD inhibitor to cancer cells in a patient.
A method for treating cancer in a patient comprising first administering eniluracil and thereafter administering 5-FU, wherein eniluracil is administered at least about 0.5 hours prior to administration of 5-FU, and wherein the 5-FU or 5-FU prodrug is administered at a dose such that at its time of administration the 5-FU or 5-FU prodrug is present in the patient in excess of the DPD inhibitor.
A method for treating cancer in a patient comprising first administering eniluracil and thereafter administering 5-FU, wherein eniluracil is administered at a dose between about 2.5-15mg/m2 at least about 12 hours before starting an extended b.i.d. schedule and thereafter the eniluracil is administered at a dose between about 0.5-2 mg/m2 at a time between about 4-6 hours before the first b.i.d. 5-FU dose of each day.
Dependencies are inferred from the claim text.